Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055161 | 0.83 | CA1 (0.70) | CA1CA2CA12CA9CA3 | |
| SCHEMBL6049162 | 0.79 | CA1 (0.46) | CA1CA2CA12CA9CA3 | |
| SCHEMBL2767866 | 0.77 | CA1 (0.44) | CA1CA2CA12CA9CA3 | |
| SCHEMBL1389216 | 0.75 | CA12 (0.46) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3070387 | 0.72 | CA1 (0.67) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3055994 | 0.71 | CA1 (0.70) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3066997 | 0.70 | CA1 (0.67) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3060788 | 0.70 | CRBN (0.48) | CA1CA2CA12CA9CA3 | |
| SCHEMBL7829614 | 0.70 | PIK3CD (0.40) | HTR6PIK3CDPIK3CGMEN1KMT2A | |
| SCHEMBL3062645 | 0.69 | HTR6 (0.55) | CA1CA2CA12CA9CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | claimed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | claimed |
| EP-1258252-B1 | INTEGRIN EXPRESSION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | claimed |
| EP-1074542-B1 | SULFONAMIDE-CONTAINING INDOLE COMPOUNDS | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | claimed |
| CN-1132814-C | Sulfonamide-containing indole compounds | EISAI CO.,LTD. (JP) | 2003-12-31 | — | — | CN | claimed |
| US-6638964-B2 | Pyridinesulfonamide containing indole compounds used as antiangiogenic and antitumor agents | EISAI CO., LTD. (JP) | 2003-10-28 | — | — | US | claimed |
| US-20020128483-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | claimed |
| EP-1074542-A1 | SULFONAMIDE-CONTAINING INDOLE COMPOUNDS | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | claimed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| EP-1258252-B1 | INTEGRIN EXPRESSION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20090269352-A1 | ANTITUMOR AGENT COMPRISING SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND COMBINED WITH AN ANGIOGENESIS INHIBITOR | WAKABAYASHI TOSHIAKI | 2009-10-29 | — | — | US | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| US-6469043-B1 | ANTIANGIOGENIC AGENT WITH ANTITUMOR, ANTIMETASTATIC PROPERTIES WHICH SHOWS HIGH SAFETY | EISAI CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| US-20020128483-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | disclosed |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | disclosed |
| CN-1294579-A | Sulfonamide-containing indole compounds | EISAI CO LTD (JP) | 2001-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269352-A1 | ANTITUMOR AGENT COMPRISING SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND COMBINED WITH AN ANGIOGENESIS INHIBITOR | FGF1, FGF2, FGFR1 | CA1 540/4885CA2 400/4885CA12 364/4885 |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | IDO1, HCCS, VEGFA | CA1 188/4885CA2 35/4885CA12 183/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | CA1 867/4885CA2 821/4885CA12 513/4885 |
| US-20020128483-A1 | Sulfonamide-containing indole compounds | IDO1, HCCS, VEGFA | CA1 160/4885CA2 27/4885CA12 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.